Mastocytosis and systemic sclerosis: A clinical association

被引：0

作者：

Bagnato G. ^{[1
]}

Roberts W.N. ^{[2
]}

Sciortino D. ^{[1
]}

Sangari D. ^{[1
]}

Cirmi S. ^{[3
]}

Ravenell R.L. ^{[2
]}

Navarra M. ^{[3
]}

Bagnato G. ^{[1
]}

Gangemi S. ^{[4
,5
]}

机构：

[1] University of Messina, Division of Rheumatology, Department of Clinical and Experimental Medicine, Messina

[2] University of Louisville, Division of Rheumatology, Department of Medicine, Louisville, KY

[3] University of Messina, Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, Messina

[4] University of Messina, School and Division of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, Messina

[5] Institute of Applied Sciences and Intelligent Systems (ISASI), Pozzuoli NA

来源：

Clinical and Molecular Allergy | / 14卷 / 1期

关键词：

Fibrosis; Mastcells; Mastocytosis; Systemic sclerosis;

D O I：

10.1186/s12948-016-0050-3

中图分类号：

学科分类号：

摘要：

Background: Systemic sclerosis (SSc) is a complex autoimmune disease characterized by vascular alterations and autoimmune activation leading to widespread organ fibrosis. At the early stage of disease when organ involvement and extent of disease are emerging, mast cells may have some role, as implied by both symptoms and histologic evidence. Case presentation: A female patient diagnosed with cutaneous mastocytosis experienced the onset of systemic sclerosis after 15 years followed by the switch of mastocytosis to the systemic phenotype. A literature review on the evidences related to mast-cells activation in systemic sclerosis is presented below. Conclusions: For clinicians, more attention must be paid to the potential association between systemic sclerosis and cancer. This case suggests that a proliferative disease in the mast cell compartment-though representing a rare association-may not be completely unexpected in SSc and perhaps excess mast cell activity can serve a pathogenic role in promoting fibrotic disease. © 2016 The Author(s).

引用

共 25 条

[1]

Desbois A.C., Cacoub P., Systemic sclerosis: an update in 2016, Autoimmun Rev, 15, 5, pp. 417-426, (2016)

[2]

Walker U.A., Tyndall A., Czirjak L., Denton C., Farge-Bancel D., Kowal-Bielecka O., Muller-Ladner U., Bocelli-Tyndall C., Matucci-Cerinic M., Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database, Ann Rheum Dis, 66, 6, pp. 754-763, (2007)

[3]

Mayes M.D., The scleroderma book: a guide for patients and families, (1999)

[4]

Steen V.D., Clinical manifestations of systemic sclerosis, Semin Cutan Med Surg, 17, pp. 48-54, (1998)

[5]

Connolly M.K., Scleroderma, Dermatol Ther, 14, pp. 81-94, (2001)

[6]

Razykov I., Thombs B.D., Hudson M., Et al., Prevalence and clinical correlates of pruritus in patients with systemic sclerosis, Arthritis Care Res, 61, pp. 1765-1770, (2009)

[7]

Hebbar M., Gillot J.M., Hachulla E., Lassalle P., Hatron P.Y., Devulder B., Janin A., Early expression of E-selectin, tumor necrosis factor alpha, and mast cell infiltration in the salivary glands of patients with systemic sclerosis, Arthritis Rheum, 39, 7, pp. 1161-1165, (1996)

[8]

Hugle T., Hogan V., White K.E., Laar J.M., Mast cells are a source of transforming growth factor β in systemic sclerosis, Arthritis Rheum, 63, 3, pp. 795-799, (2011)

[9]

Irani A.M., Gruber B.L., Kaufman L.D., Kahaleh M.B., Schwartz L.B., Mast cell changes in scleroderma. Presence of MCT cells in the skin and evidence of mast cell activation, Arthritis Rheum, 35, 8, pp. 933-939, (1992)

[10]

Akimoto S., Ishikawa O., Igarashi Y., Kurosawa M., Miyachi Y., Dermal mast cells in scleroderma: their skin density, tryptase/chymase phenotypes and degranulation, Br J Dermatol, 138, 3, pp. 399-406, (1998)

← 1 2 3 →